Company Overview and News

1
Clayton office fetches $24.6m from IOOF Holdings Limited

2018-05-25 theage.com.au
The first investment grade office to hit the market this year has sold to IOOF Holdings Limited for $24.6 million – some $2 million above expectation.
PMV IOOFF IFL IOOFY JLL

1
Clayton office fetches $24.6m from IOOF Holdings Limited

2018-05-25 smh.com.au
The first investment grade office to hit the market this year has sold to IOOF Holdings Limited for $24.6 million – some $2 million above expectation.
PMV IOOFF IFL IOOFY JLL

9
Australia’s ANZ cuts financial planner bonuses as inquiry reshapes an industry

2018-05-07 thestar.com.my
SYDNEY: Australia’s ANZ said it would quit paying bonuses to financial planners for selling its products, becoming the country’s first major lender to change business practices in response to a powerful inquiry that has unmasked widespread misconduct in the sector. The move by Australia and New Zealand Banking Group Ltd highlights how the Royal Commission has started to refashion an industry central to the world’s 12th largest economy, just three months into what is scheduled to be a year-long run.
NAUBF WBC IOOFF WBC IFL AMP NAB NASXF IOOFY WEBNF NABZY WBK

9
Australia's ANZ cuts financial planner bonuses as inquiry reshapes an industry

2018-05-07 reuters
SYDNEY (Reuters) - Australia’s ANZ said it would quit paying bonuses to financial planners for selling its products, becoming the country’s first major lender to change business practices in response to a powerful inquiry that has unmasked widespread misconduct in the sector.
NAUBF WBC IOOFF WBC IFL AMP NAB NASXF IOOFY WEBNF NABZY WBK

2
‘Golden Period’ of Australian Banking Over, ANZ Bank Chief Says - Bloomberg

2018-05-01 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ZURVY IOOFF IFL IOOFY ZFSVF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:IFL / IOOF HOLDINGS LIMITED on message board site Silicon Investor.

IFLB - Infinium Labs, Inc. IFLO Corporation
IFLY - travel sales on the web pure play NIFL Nova International Films
VIFL IFLO is Breaking Out
AFFT BREAKING OUT--THE NEXT IFLY IFLY - A civil approach
I am long IFLY go ahead and short it THE NEXT IFLY--TRIP